Advertisement

Topics

FDA Panel Supports Licensing Two-Dose Hep B Vaccine

02:28 EDT 30 Jul 2017 | Medscape

Concerns of a possible link with myocardial infarction remain, but benefits beat risks, the committee says. Members call for clearer design with the postmarketing study the company proposes.
Medscape Medical News

Original Article: FDA Panel Supports Licensing Two-Dose Hep B Vaccine

NEXT ARTICLE

More From BioPortfolio on "FDA Panel Supports Licensing Two-Dose Hep B Vaccine"

Quick Search
Advertisement